Form 4: ARTIVION CEO Boosts Stake with New Stock Grant

ARTIVION, INC. President & CEO James P. Mackin increased his beneficial ownership by 62,132 shares following a restricted stock grant, despite 'sell to cover' tax transactions.

Summary

• James P. Mackin, President & CEO of ARTIVION, INC. (AORT), reported transactions on February 23 and 24, 2026.
• Mackin sold 20,962 shares of common stock at $37.588 on February 23, 2026, to cover tax withholding obligations upon the vesting of performance stock units.
• On February 24, 2026, he sold an additional 13,936 shares of common stock at $35.693 to cover tax withholding obligations upon the vesting of restricted stock units.
• These sales were non-discretionary 'sell to cover' transactions.
• Concurrently, on February 24, 2026, Mackin acquired 97,030 shares of restricted stock at a price of $0.
• These newly acquired restricted shares will vest 33 1/3% per year starting on the first anniversary of the grant date, under the company's Equity and Cash Incentive Plan.
• Following these transactions, Mackin's direct beneficial ownership of ARTIVION common stock increased from 800,993 shares (prior to these reported transactions) to 863,125 shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal. While there were sales, they were non-discretionary for tax purposes, and the CEO's overall beneficial ownership increased significantly due to a new equity grant, indicating continued alignment and long-term commitment.

Positives

• President & CEO James P. Mackin's beneficial ownership increased by 62,132 shares, indicating continued alignment with shareholder interests.
• The acquisition of 97,030 shares of restricted stock at $0 demonstrates ongoing equity-based compensation and retention of key management.
• The vesting schedule of 33 1/3% per year over three years for the restricted stock grant suggests a long-term incentive structure.

Negatives

• Sales of 34,898 shares (20,962 + 13,936) occurred, although these were non-discretionary 'sell to cover' transactions for tax obligations.

Future Outlook

The grant of restricted stock units with a multi-year vesting schedule indicates a long-term incentive strategy for the President & CEO, aligning his future compensation with the company's sustained performance.

Management Comments

• These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction.
• These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction.
• Represents shares of restricted stock that vest 33 1/3% per year beginning on the first anniversary of the grant date, pursuant to the terms of the Equity and Cash Incentive Plan.

Industry Context

StockSavvy.ai notes that 'sell to cover' transactions are a common practice for executives receiving equity compensation, allowing them to meet tax obligations without needing to use personal funds. The net increase in beneficial ownership for the CEO, despite these sales, suggests a positive long-term commitment to the company, which is generally viewed favorably by the market.

Comparison to Industry Standards

• Equity compensation, including restricted stock units and performance stock units, is a standard practice across industries, particularly in the medical device and biotechnology sectors where ARTIVION operates, to align executive incentives with long-term shareholder value.
• The vesting schedule of 33 1/3% per year over three years is a common structure for executive equity grants, comparable to practices at companies like Medtronic (MDT) or Edwards Lifesciences (EW) for their executive compensation plans.
• 'Sell to cover' transactions are a widely accepted and non-discretionary method for executives to manage tax liabilities arising from equity vesting, seen across all publicly traded companies with equity compensation programs.

Stakeholder Impact

• Shareholders: The increase in CEO's beneficial ownership aligns management interests with shareholder value creation. The 'sell to cover' transactions are routine and not indicative of a lack of confidence.
• Employees: The equity grant to the CEO reinforces the company's compensation strategy, which may influence broader employee incentive programs.

Next Steps

• The newly acquired restricted stock will vest 33 1/3% per year beginning on the first anniversary of the grant date.

Key Dates

Recommendation

The filing details routine insider transactions where the CEO received a significant equity grant and simultaneously sold shares to cover tax obligations. The net effect is an increase in the CEO's beneficial ownership, which is a positive sign of alignment. However, these are not discretionary purchases and do not provide new fundamental information about the company's operational performance or strategic direction to warrant a 'buy' or 'sell' recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting further operational updates.

Keywords

ARTIVION, AORT, Form 4, Insider Trading, Beneficial Ownership, CEO, James P. Mackin, Restricted Stock Units, Performance Stock Units, Equity Compensation, Sell to Cover